Brief: VBI Vaccines Receives U.S. FDA Orphan Drug Designation For Vbi-1901 For The Treatment Of Glioblastoma
22/06/2022 13:28
June 22 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR
VBI-1901 FOR THE TREATMENT OF GLIOBLASTOMA
Source text for Eikon: ID:nBw1HqysXa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55